Physician profile
Adele Amine
NPI 1891155099
$1,343.07
in general payments reported to CMS, 2019-2025
20 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $619 · 2023: $29.27 · 2024: $233 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $284.93 | 2021-2022 | |
| Lilly USA, LLC | $212.68 | 2022-2024 | Mounjaro |
| Insulet Corporation | $143.65 | 2022-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.41 | 2021-2023 | Tradjenta |
| Beta Bionics, INC. | $107.85 | 2024 | Ilet Bionic Pancreas |
| Medtronic, INC. | $90.18 | 2021-2022 | |
| Madrigal Pharmaceuticals | $59.37 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $52.60 | 2022 | |
| Abbott Laboratories | $31.96 | 2022 | |
| Eusa Pharma (US) LLC | $25.69 | 2022 | |
| Recordati_rare_diseases_inc. | $25.69 | 2022 | |
| Dexcom, INC. | $24.42 | 2022 | |
| Radius Health, INC. | $23.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.39 | 2025 | |
| Corcept Therapeutics | $23.10 | 2025 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $21.82 | 2022 | |
| Cequr Corporation | $21.04 | 2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $20.53 | 2025 | |
| Ascensia Diabetes Care US INC. | $19.05 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.14 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adele Amine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.